Lung function in adult patients with cystic fibrosis after using the eFlow® rapid for one year

European Journal of Medical Research

Volumn 16, Issue 2, 2011, Pages 63-66

  Naehrig, Susanne ^a   Lang, S ^b   Schiffl, H ^c   Huber, R M ^a   Fischer, R ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b SRH Wald Klinikum Gera   (Germany)

^c Kuratorium für Hämodialyse   (Germany)

Author keywords

Cystic fibrosis; eFlow rapid; Inhalation; Inhalation time; Lung function; Nebuliser

Indexed keywords

COLISTIN; TOBRAMYCIN; TOBRAMYCIN SULFATE;

ADULT; ARTICLE; COMPARATIVE STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LONG TERM CARE; LUNG CYSTIC FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL NEBULIZER; PATIENT SATISFACTION; TREATMENT DURATION; NEBULIZER; RETROSPECTIVE STUDY;

EID: 79952776208     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-2-63     Document Type: Article

References (11)

1. Boyle MP. Adult Cystic Fibrosis. JAMA 2007; 298(15): 1787-93
2. Flume PA, O'Sullivan BP, Robinson KA et al. Cystic Fibrosis Guidelines: Chronic Medications for Maintenance of Lung Health. Am J Respir Crit Care Med. 2007 Aug 29; [Epub ahead of print]
3. Friedrichs F, Keller M, Döhmen H, Pfannenstiel C, Ledermüller R. Comparison of tobramycin serum plasma levels in 5 CF patients after inhalation via PARI LC PLUS® nebuliser and via eFlow®, a novel electronic inhaler. Journal of Cystic Fibrosis, vol 3, suppl 1, S64; 2004
4. Tavakkol A, Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, Maykut R, Stenglein S, Kovarik J. Tobramycin inhaled solution (TOBI) administered via PARI eFlow® rapid electronic nebuliser may yield a higher therapeutic ratio vs PARI LC Plus Jet nebuliser in cystic fibrosis patients. Ped Pulmonol 2007, Suppl. 30, A249.
5. Militz S, Feilcke M, Schröter C, Kraxner A, Eismann C, Griese M, Kappler M. eFlow® rapid: improved lung function and patient satisfaction with more volume delivered tot he lungs during inhalation therapy in cystic fibrosis. Journal of Cystic Fibrosis Vol 7, Suppl. 2, page S67, 2008
6. Seemann S, Hug M, Lichtinghagen R, Schmitt A, Tservistas M, Waldner R, Knoch M: Improving aerosol drug delivery in CF therapy. J Cystic Fibrosis 2005; Suppl , abstract 113.
7. Scherer T, Geller DE, Owyang L, Tservistas M, Keller M, Boden N, Kesser KC, Shire Sj. A Technical Feasibility Study of Dornase Alfa Delivery with eFlow® Vibrating Membrane Nebulizers: AerosolCharacteristics and Physicochemical Stability. Journal of Pharamceutical Sciences, Juni 8, 2010 (Epub ahead of print)
8. Geidel C, Bittner-Dersch P, Schüler D, Weber K, Lindemann H: Tobramycin-Spiegel im Serum bei unterschiedlichen Positionen des eFlow® rapid. Atemwegs-Lungenkrkh. 2006;32:118
9. Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, Delaisi B, Kho P, Kovarik JM. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis. Journal of Cystic Fibrosis, 8 (5): 332-7; 2009
10. Coates AL, Leung K, Green M, Chan J, Ribeiro N, Martin S, Menges G, Keller M, Charron M, Ratjen F. A rapid way to deliver high doses of tobramycin to the airways of adul and pediatric patients with cystic fibrosis. Ped Pulmonol 2007, Supp. 30, A343
11. Thuilliez C, Laurans M, Morello R, Duhamel JF, Brouard J. Effect on quality of life and treatment adherence of nebulaisation's duration in cystic fibrosis (CF). Journal of Cystic Fibrosis, Vol. 7, Suppl. 2, page S67; 2008.